Aldeyra Therapeutics (ALDX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

ALDX Stock Forecast


Aldeyra Therapeutics stock forecast is as follows: an average price target of $11.00 (represents a 112.36% upside from ALDX’s last price of $5.18) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

ALDX Price Target


The average price target for Aldeyra Therapeutics (ALDX) is $11.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $10.00. This represents a potential 112.36% upside from ALDX's last price of $5.18.

ALDX Analyst Ratings


Buy

According to 2 Wall Street analysts, Aldeyra Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ALDX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aldeyra Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 03, 2024Justin KimOppenheimer$12.00$5.14133.46%131.66%
Apr 03, 2024Justin KimOppenheimer$10.00$3.55181.69%93.05%
Apr 02, 2024Matt CaufieldH.C. Wainwright$10.00$3.27205.81%93.05%
Row per page
Go to

The latest Aldeyra Therapeutics stock forecast, released on Oct 03, 2024 by Justin Kim from Oppenheimer, set a price target of $12.00, which represents a 133.46% increase from the stock price at the time of the forecast ($5.14), and a 131.66% increase from ALDX last price ($5.18).

Aldeyra Therapeutics Price Target by Period


1M3M12M
# Anlaysts-13
Avg Price Target-$12.00$10.67
Last Closing Price$5.18$5.18$5.18
Upside/Downside-100.00%131.66%105.98%

In the current month, the average price target of Aldeyra Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aldeyra Therapeutics's last price of $5.18. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 03, 2024OppenheimerOutperformOutperformHold
Apr 03, 2024Oppenheimer-OutperformUpgrade
Jun 09, 2022CitigroupBuyBuyHold
Row per page
Go to

Aldeyra Therapeutics's last stock rating was published by Oppenheimer on Oct 03, 2024. The company gave ALDX a "Outperform" rating, the same as its previous rate.

Aldeyra Therapeutics Financial Forecast


Aldeyra Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
Revenue--------$392.62K-
Avg Forecast----$33.17M--$1.20M$3.00M$-46.00
High Forecast----$33.17M--$1.20M$3.00M$-46.00
Low Forecast----$33.17M--$1.20M$3.00M$-46.00
# Analysts----4--242
Surprise %--------0.13%-

Aldeyra Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.20M, with a low forecast of $1.20M, and a high forecast of $1.20M. ALDX's average Quarter revenue forecast represents a 205.64% increase compared to the company's last Quarter revenue of $392.62K (Dec 23).

Aldeyra Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
EBITDA--------$-13.97M$-15.31M
Avg Forecast----------
High Forecast----------
Low Forecast----------
Surprise %----------

undefined analysts predict ALDX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aldeyra Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aldeyra Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
Net Income--------$-5.45M$-15.79M
Avg Forecast$-15.45M$-15.45M$-13.67M$-13.67M$9.61M$-14.68M$-12.26M$-6.57M$-6.57M$-15.62M
High Forecast$-15.45M$-15.45M$-13.67M$-13.67M$9.61M$-9.40M$-12.26M$-6.57M$-5.63M$-15.62M
Low Forecast$-15.45M$-15.45M$-13.67M$-13.67M$9.61M$-17.03M$-12.26M$-6.57M$-6.88M$-15.62M
Surprise %--------0.83%1.01%

Aldeyra Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aldeyra Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
SG&A--------$1.80M$2.55M
Avg Forecast----------
High Forecast----------
Low Forecast----------
Surprise %----------

Aldeyra Therapeutics's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ALDX last annual SG&A of $1.80M (Dec 23).

Aldeyra Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 21
# Analysts----4--242
EPS--------$-0.09$-0.27
Avg Forecast$-0.26$-0.26$-0.23$-0.23$0.16$-0.25$-0.21$-0.11$-0.11$-0.26
High Forecast$-0.26$-0.26$-0.23$-0.23$0.16$-0.16$-0.21$-0.11$-0.09$-0.26
Low Forecast$-0.26$-0.26$-0.23$-0.23$0.16$-0.29$-0.21$-0.11$-0.12$-0.26
Surprise %--------0.84%1.03%

According to undefined Wall Street analysts, Aldeyra Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALDX previous annual EPS of $NaN (undefined).

Aldeyra Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
LXRXLexicon Pharmaceuticals$1.21$6.00395.87%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
ETNB89bio$9.29$22.00136.81%Buy
GPCRStructure Therapeutics$39.74$92.40132.51%Buy
ALDXAldeyra Therapeutics$5.18$11.00112.36%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
LYRALyra Therapeutics$0.26$0.5092.31%Hold
VRDNViridian Therapeutics$22.84$37.8365.63%Buy
ETONEton Pharmaceuticals$8.35$13.0055.69%Buy
MCRBSeres Therapeutics$0.81$1.2554.32%Buy
IBRXImmunityBio$5.20$8.0053.85%Buy
ARDXArdelyx$5.89$8.7548.56%Buy
PHATPhathom Pharmaceuticals$18.94$25.8336.38%Buy
TARSTarsus Pharmaceuticals$46.21$62.0034.17%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
TVTXTravere Therapeutics$18.10$21.3818.12%Buy
HOOKHOOKIPA Pharma$3.76$3.00-20.21%Buy

ALDX Forecast FAQ


Yes, according to 2 Wall Street analysts, Aldeyra Therapeutics (ALDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ALDX's total ratings.

Aldeyra Therapeutics (ALDX) average price target is $11 with a range of $10 to $12, implying a 112.36% from its last price of $5.18. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for ALDX stock, the company can go up by 112.36% (from the last price of $5.18 to the average price target of $11), up by 131.66% based on the highest stock price target, and up by 93.05% based on the lowest stock price target.

ALDX's average twelve months analyst stock price target of $11 supports the claim that Aldeyra Therapeutics can reach $8 in the near future.

Aldeyra Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $34.37M (high $34.37M, low $34.37M), average EBITDA is $0 (high $0, low $0), average net income is $-23.904M (high $-18.618M, low $-26.253M), average SG&A $0 (high $0, low $0), and average EPS is $-0.402 (high $-0.313, low $-0.442). ALDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-58.226M (high $-58.226M, low $-58.226M), average SG&A $0 (high $0, low $0), and average EPS is $-0.98 (high $-0.98, low $-0.98).

In terms of the last quarterly report (Dec 2023), Aldeyra Therapeutics's revenue was $392.62K, missing the average analysts' forecast of $3M by -86.91%. The company's EBITDA was $-13.975M, beating the average prediction of $0 by 0%. Aldeyra Therapeutics's net income was $-5.449M, missing the average estimation of $-6.566M by -17.01%. The company's SG&A was $1.8M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-0.0924, missing the average prediction of $-0.111 by -16.40%